menu
    • menu
    [{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Quemliclustat","moa":"enzyme inhibitors","graph1":"Undisclosed","graph2":"Phase I","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Arcus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Quemliclustat","moa":"enzyme inhibitors","graph1":"Oncology","graph2":"Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arcus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Quemliclustat","moa":"enzyme inhibitors","graph1":"Undisclosed","graph2":"Phase I","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Arcus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Quemliclustat","moa":"||enzyme inhibitors","graph1":"Oncology","graph2":"Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arcus Biosciences \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Arcus Biosciences \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Quemliclustat","moa":"||enzyme inhibitors","graph1":"Oncology","graph2":"Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arcus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arcus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Quemliclustat","moa":"||enzyme inhibitors","graph1":"Oncology","graph2":"Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Arcus Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Quemliclustat","moa":"||enzyme inhibitors","graph1":"Oncology","graph2":"Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arcus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arcus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Quemliclustat","moa":"enzyme inhibitors","graph1":"Oncology","graph2":"Phase III","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcus Biosciences \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Arcus Biosciences \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Catherine Spina","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Quemliclustat","moa":"enzyme inhibitors","graph1":"Oncology","graph2":"Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcus Biosciences \/ Catherine Spina","highestDevelopmentStatusID":"8","companyTruncated":"Arcus Biosciences \/ Catherine Spina"}]

    Find Clinical Drug Pipeline Developments & Deals for Quemliclustat

    Menu

    Quemliclustat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Arcus Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Arcus Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quemliclustat

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Taiho Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic...

                            Details : Quemliclustat is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Pancreatic Ductal.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 23, 2024

                            Lead Product(s) : Quemliclustat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Taiho Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Arcus Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Arcus Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quemliclustat,Etrumadenant,Zimberelimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Taiho Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Taiho Exercises License Option for Quemliclustat in Japan and Asia

                            Details : Under the license agreement, Taiho will further support the development & commercialization of AB680 (quemliclustat) & will operationalize the PRISM-1 study in Japan as part of its mission.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 08, 2024

                            Lead Product(s) : Quemliclustat,Etrumadenant,Zimberelimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Taiho Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Arcus Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Arcus Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quemliclustat,Paclitaxel,Zimberelimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Gilead Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Quemliclustat-Based Regimens Show Promising Survival in Metastatic Pancreatic Cancer

                            Details : AB680 (quemliclustat) is an investigational small molecule CD73 inhibitor in phase 1 development, evaluated in combination with chemotherapy for treatment-naïve metastatic pancreatic cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 16, 2024

                            Lead Product(s) : Quemliclustat,Paclitaxel,Zimberelimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Gilead Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Arcus Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Arcus Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quemliclustat,Paclitaxel,Zimberelimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Quemliclustat-Based Regimens Show Survival Promise in Metastatic Pancreatic Cancer

                            Details : AB680 (quemliclustat) is an investigational CD73 inhibitor undergoing phase 1 trials in combination with zimberelimab and chemotherapy for metastatic pancreatic cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 16, 2024

                            Lead Product(s) : Quemliclustat,Paclitaxel,Zimberelimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Arcus Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Arcus Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quemliclustat

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Catherine Spina

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostat...

                            Details : Quemliclustat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 23, 2023

                            Lead Product(s) : Quemliclustat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Catherine Spina

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Arcus Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Arcus Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quemliclustat,Paclitaxel,Zimberelimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Arcus Biosciences to Present Preliminary Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Panc...

                            Details : Preliminary data from the first dose-escalation cohorts, reported in an abstract released today, demonstrate encouraging signs of clinical activity for AB680 in combination with zimberelimab (anti-PD-1 antibody) and chemotherapy.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 11, 2021

                            Lead Product(s) : Quemliclustat,Paclitaxel,Zimberelimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Arcus Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Arcus Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quemliclustat

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers

                            Details : AB680 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 05, 2020

                            Lead Product(s) : Quemliclustat

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Arcus Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Arcus Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quemliclustat

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

                            Details : AB680 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pancreatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 26, 2019

                            Lead Product(s) : Quemliclustat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Arcus Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Arcus Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quemliclustat

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Safety of AB680 in Healthy Volunteers

                            Details : AB680 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 19, 2018

                            Lead Product(s) : Quemliclustat

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth